Interim Estimates of 2021-22 Seasonal Influenza Vaccine Effectiveness - United States, February 2022 [0.03%]
2021-22流感季节性流感疫苗效力的中期估算结果——美国，2022年2月
Jessie R Chung,Sara S Kim,Rebecca J Kondor et al.
Jessie R Chung et al.
In the United States, annual vaccination against seasonal influenza is recommended for all persons aged ≥6 months except when contraindicated (1). Currently available influenza vaccines are designed to protect against four influenza viruse...
SARS-CoV-2 Incidence in K-12 School Districts with Mask-Required Versus Mask-Optional Policies - Arkansas, August-October 2021 [0.03%]
2021年8—10月美国阿肯色州K-12学区要求佩戴口罩与不要求佩戴口罩的学校冠状病毒疾病2019发病率比较研究报告
Catherine V Donovan,Charles Rose,Kanna N Lewis et al.
Catherine V Donovan et al.
Masks are effective at limiting transmission of SARS-CoV-2, the virus that causes COVID-19 (1), but the impact of policies requiring masks in school settings has not been widely evaluated (2-4). During fall 2021, some school districts in Ar...
COVID-19 Vaccine Provider Access and Vaccination Coverage Among Children Aged 5-11 Years - United States, November 2021-January 2022 [0.03%]
2021年11月～2022年1月美国5-11岁儿童的新冠疫苗供应和接种覆盖率
Christine Kim,Randy Yee,Roma Bhatkoti et al.
Christine Kim et al.
On October 29, 2021, the Pfizer-BioNTech pediatric COVID-19 vaccine received Emergency Use Authorization for children aged 5-11 years in the United States.† For a successful immunization program, both access to and uptake of the vaccine ar...
Evaluation of Serologic Cross-Reactivity Between Dengue Virus and SARS-CoV-2 in Patients with Acute Febrile Illness - United States and Puerto Rico, April 2020-March 2021 [0.03%]
评估登革病毒和SARS-CoV-2感染急性发热患者血清学交叉反应性——美国和波多黎各，2020年4月—2021年3月
Jorge Munoz-Jordan,Jaime Cardona,Manuela Beltrán et al.
Jorge Munoz-Jordan et al.
The diagnosis of dengue disease, caused by the dengue virus (DENV) (a flavivirus), often requires serologic testing during acute and early convalescent phases of the disease. Some symptoms of DENV infection, such as nonspecific fever, are s...
Notes from the Field: Readiness for Use of Type 2 Novel Oral Poliovirus Vaccine in Response to a Type 2 Circulating Vaccine-Derived Poliovirus Outbreak - Tajikistan, 2020-2021 [0.03%]
现场笔记：准备使用II型新型口服脊髓灰质炎病毒疫苗应对2020-2021年塔吉克斯坦循环疫苗衍生脊髓灰质炎病毒疫情
Patrick O&#x;Connor,Shahin Huseynov,Carrie F Nielsen et al.
Patrick O&#x;Connor et al.
Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12-17 Years - United States, December 9, 2021-February 20, 2022 [0.03%]
2021年12月9日至2022年2月20日美国12-17岁人群新冠疫苗加强剂的安全监测报告
Anne M Hause,James Baggs,Paige Marquez et al.
Anne M Hause et al.
As of February 20, 2022, only BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine has been authorized for use in persons aged 12-17 years in the United States (1). The Food and Drug Administration (FDA) amended the Emergency Use Authorization (EUA)...
Disparities in COVID-19 Vaccination Coverage Between Urban and Rural Counties - United States, December 14, 2020-January 31, 2022 [0.03%]
2020年12月14日至2022年1月31日美国城市和农村县的COVID-19疫苗接种覆盖率差异
Ryan Saelee,Elizabeth Zell,Bhavini Patel Murthy et al.
Ryan Saelee et al.
Higher COVID-19 incidence and mortality rates in rural than in urban areas are well documented (1). These disparities persisted during the B.1.617.2 (Delta) and B.1.1.529 (Omicron) variant surges during late 2021 and early 2022 (1,2). Rural...
Notes from the Field: First Reports of Locally Transmitted Seoul Hantavirus Infection - District of Columbia, May 2018-December 2018 [0.03%]
现场观察：2018年5月—12月 首次报告本地发现塞oul汉病毒传染病例-哥伦比亚特区
Nivedita Ravi-Caldwell,Preetha Iyengar,John Davies-Cole
Nivedita Ravi-Caldwell
Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022 [0.03%]
在2021年4月至2022年1月期间对5-17岁非免疫功能低下儿童和青少年预防因新冠病毒感染而急诊和门诊就诊及住院的效果：VISION网络10州地区数据报告（ Pfizer-BioNTech BNT162b2 mRNA新冠疫苗）
Nicola P Klein,Melissa S Stockwell,Maria Demarco et al.
Nicola P Klein et al.
The efficacy of the BNT162b2 (Pfizer-BioNTech) vaccine against laboratory-confirmed COVID-19 exceeded 90% in clinical trials that included children and adolescents aged 5-11, 12-15, and 16-17 years (1-3). Limited real-world data on 2-dose m...